Prolia (Denosumab) in Children Under 12: What Happens at the Transition to Adult Care

Why Denosumab Is Used Off-Label in Young Children

Denosumab is not FDA-approved for patients under 18. Children do receive it. When standard bisphosphonate regimens fail, or when a child has a contraindication to bisphosphonates, pediatric endocrinologists and metabolic bone specialists turn to denosumab because its mechanism is directly relevant to the underlying pathology in several rare diseases.

The RANK/RANKL Pathway in Growing Bone

Denosumab binds RANK ligand (RANKL), blocking osteoclast formation and reducing bone resorption. In adults this is straightforward suppression of turnover. In children, the growing skeleton remodels at a far higher rate than adult bone. Suppressing osteoclast activity in a pediatric patient alters not only resorption but the coupling signal that drives new bone formation at growth plates and cortical envelopes. A 2019 paper in the Journal of Bone and Mineral Research documented hypercalcemia in 64% of children treated with denosumab for giant cell tumor of bone, a rate dramatically higher than in adult cohorts (1).

Conditions That Lead to Denosumab Use Before Age 12

The three most common scenarios in clinical practice are:

• Osteogenesis imperfecta (OI) where bisphosphonate response is inadequate or gastrointestinal intolerance is severe
• Glucocorticoid-dependent conditions (juvenile dermatomyositis, nephrotic syndrome) causing secondary osteoporosis with ongoing steroid exposure that bisphosphonates cannot fully offset
• RANK-pathway disorders such as juvenile Paget disease or expansile skeletal hyperphosphatasia, where RANKL dysregulation is the primary defect

The Endocrine Society's 2017 Clinical Practice Guideline on Pediatric Osteoporosis states: "Bisphosphonates remain the first-line agents; anti-RANKL therapy may be considered in patients with contraindications or inadequate response." (2)

The Core Problem: Rebound After Denosumab Discontinuation

This is the clinical fact that every physician receiving a transitioning pediatric patient must internalize before the first appointment. Stopping denosumab without a plan is not a neutral act.

What Rebound Actually Looks Like

When denosumab clears, RANKL activity surges above baseline. Bone turnover markers (serum CTX, urine NTX) spike sharply, often to levels exceeding pre-treatment values. In adults this rebounds to near-normal over 12 months; in children, the rebound is faster, steeper, and more clinically dangerous because baseline turnover was already high. A prospective cohort published in Osteoporosis International (N=27 pediatric patients, mean age 11.3 years) found that CTX levels peaked at roughly 3 times the upper limit of normal within 3 to 4 months of the last dose (3).

Vertebral Fracture Risk Is Real and Documented

Multiple case series document new or worsening vertebral fractures in pediatric patients within 8 to 16 months of denosumab discontinuation. A 2020 case series in the Journal of Clinical Endocrinology and Metabolism reported vertebral fractures in 4 of 9 children (44%) who stopped denosumab without bisphosphonate bridging (4). These were not incidental radiographic findings. Three of the four children had clinically significant back pain and one required vertebroplasty.

Hypercalcemia at Transition

Rebound hypercalcemia is a separate and underappreciated risk in young children. As osteoclast activity surges, calcium efflux from bone temporarily exceeds renal clearance capacity. Symptoms range from nausea and polyuria to cardiac arrhythmia in severe cases. Serum calcium should be checked at 1, 3, and 6 months after the last denosumab dose regardless of whether bisphosphonate bridging is in place.

Building the Transition Plan: What Needs to Happen Before the Handoff

Transition is not an event. It is a process that should start at least 6 months before the child's 12th birthday or the planned transfer date, whichever comes first.

Documentation the Receiving Adult Team Must Have

The adult endocrinologist or rheumatologist accepting this patient needs a complete summary that includes:

1. Date of first denosumab dose and total number of doses received
2. Indication and whether the underlying disease is still active
3. Baseline and most recent DXA results with age- and sex-matched Z-scores (not T-scores, which are invalid in pediatric patients)
4. Bone turnover markers at baseline, peak suppression, and most recent measurement
5. Any prior fractures, including vertebral morphometry results
6. Bisphosphonate history before denosumab was started
7. Current calcium and vitamin D status with supplementation doses

Without these seven data points, the adult physician is managing a drug effect they cannot contextualize. One of the most common errors at transition is an adult provider who sees a suppressed CTX, assumes the patient is "well-controlled," and plans to continue denosumab on the standard adult schedule without recognizing that no fracture prevention bridging plan was ever made.

Timing the Last Pediatric Dose Relative to Transition

The last dose administered by the pediatric team should be timed so that the adult team receives the patient no more than 3 months before the next dose is due. If the next dose interval falls in the gap between providers, a specific written protocol must document which provider will administer it and what monitoring is required.

A practical framework used at quaternary pediatric bone centers divides the transition into three phases:

Phase 1 (6 months before transfer): Confirm the adult receiving provider. Share records. Order a DXA and a full bone panel (CTX, P1NP, calcium, phosphate, 25-OH vitamin D, PTH, renal function).

Phase 2 (3 months before transfer): Joint appointment with both the outgoing pediatric specialist and the incoming adult specialist if geographically feasible, or a shared telehealth review. At this visit, decide whether denosumab will continue, be bridged to a bisphosphonate, or be discontinued without bridging (rarely appropriate).

Phase 3 (transfer appointment): Patient and caregiver receive a written medication passport listing drug name, dose, date of last injection, date of next injection, and a 24-hour contact number for either care team in case of symptomatic hypercalcemia.

Bisphosphonate Bridging: The Standard of Care for Discontinuation

When the decision is made to stop denosumab at or after the transition, bisphosphonate bridging is the current standard of care based on adult data and extrapolated to pediatrics by expert consensus.

Which Bisphosphonate and When

Zoledronic acid (5 mg IV in adults; weight-based dosing in children, typically 0.05 mg/kg up to 4 mg per infusion) is the most commonly used bridging agent because of its long skeletal retention. A 2021 retrospective analysis in Bone (N=43 adults) showed that a single zoledronic acid infusion given 6 months after the last denosumab dose reduced rebound-associated vertebral fracture incidence from 38% to 9% (P<0.01) (5).

Pediatric data are thinner, but the mechanistic rationale is the same. Oral alendronate (70 mg weekly in older children, weight-adjusted in younger patients) is used when IV access is a barrier or when patient preference strongly favors oral therapy.

Timing the Bridge

The bisphosphonate should be started 6 months after the last denosumab dose, which corresponds approximately to when serum CTX begins to rise. Starting too early may blunt the mild physiologic remodeling that occurs as denosumab clears; starting too late leaves a window of unprotected rebound. Some centers start the bisphosphonate at the time of the last denosumab dose itself; outcomes data comparing these two approaches in pediatric patients are not yet available.

Monitoring After Bridging

CTX and P1NP should be measured at 3 and 6 months after bisphosphonate initiation. If CTX remains more than twice the upper limit of normal at 6 months, a second bisphosphonate dose is warranted. Serum calcium monitoring continues on the same schedule described above.

DXA Interpretation Across the Transition: Avoiding Scope Errors

DXA interpretation differs materially between pediatric and adult reporting standards. This difference becomes a patient safety issue at transition.

Z-Scores vs. T-Scores

Pediatric DXA uses Z-scores referenced against age and sex-matched peers. A Z-score of -2.0 in a 10-year-old is clinically significant. The adult convention shifts to T-scores referenced against young adult peak bone mass, which makes T-scores meaningless in a patient who has not yet reached peak bone mass. Adult providers who default to T-score reporting on a transitioning patient may underestimate or overestimate fracture risk.

The International Society for Clinical Densitometry (ISCD) 2019 Pediatric Official Positions state: "In children and adolescents, the diagnosis of osteoporosis should not be made on the basis of densitometric criteria alone." Fracture history, clinical context, and growth trajectory all matter (6).

Lumbar Spine vs. Total Body Less Head

Pediatric DXA typically reports lumbar spine (L1-L4) and total body less head (TBLH). Adult protocols often emphasize femoral neck and total hip. At transition, the adult team should continue to scan the lumbar spine for longitudinal comparability. Switching sites breaks the trend line that the pediatric team spent years building.

Special Considerations for Children With Osteogenesis Imperfecta

OI deserves its own discussion because it accounts for a disproportionate share of pediatric denosumab use and because the transition risk profile differs from idiopathic or glucocorticoid-induced osteoporosis.

Why OI Patients Are Higher Risk at Transition

Children with OI types III and IV have structurally defective collagen regardless of bone density improvement on therapy. A DXA-based Z-score improvement does not mean the bone matrix quality is normal. When rebound occurs in an OI patient, the risk of fracture is compounded by baseline matrix fragility. A 2018 case report series in Pediatric Rheumatology documented multiple vertebral compression fractures in three OI children aged 8 to 11 within 6 months of denosumab discontinuation, all of whom had shown Z-score improvement on treatment (7).

Continuing Denosumab Into Adulthood for OI

For severe OI, the safest path may be to continue denosumab into adult care rather than transition to a bisphosphonate. Adult Prolia dosing (60 mg every 6 months subcutaneously) is FDA-approved for postmenopausal osteoporosis and male osteoporosis at high fracture risk. An adult physician can continue this regimen with appropriate monitoring. The critical requirement is that no dose is missed and that a concrete plan for eventual discontinuation exists, with bisphosphonate bridging built in from day one.

Communication Protocols and Caregiver Education

What Caregivers Must Understand Before Transfer

Caregivers of children under 12 are the primary advocates for medication adherence during the transition period. They need to know:

• Denosumab works only while it is being given on schedule. Missing a dose by more than 4 to 6 weeks carries measurable fracture risk.
• The adult provider must be confirmed before the pediatric provider discharges the patient from the practice.
• Symptoms of hypercalcemia (nausea, confusion, polyuria, muscle weakness) require same-day evaluation, not a wait-and-see approach.

A written medication passport handed to the caregiver at the final pediatric visit, not mailed later, is the minimum standard. The passport should list the prescribing adult physician's name and direct phone number.

Pharmacy Coordination

Prolia requires a specialty pharmacy and, at the adult dose, a REMS program in the United States for certain indications. Pediatric pharmacies often have different specialty pharmacy contracts than adult hospital systems. Verifying that the adult system's specialty pharmacy can dispense and that prior authorization transfers without a gap takes 4 to 6 weeks on average. Start this process at Phase 1, not Phase 3.

Laboratory and Clinical Monitoring Schedule at Transition

The following schedule is consistent with Endocrine Society recommendations and standard practice at quaternary pediatric bone centers (2):

| Timepoint | Tests Required | |---|---| | 3 months before last pediatric dose | DXA (LS + TBLH), CTX, P1NP, Ca, Phos, 25-OH VitD, PTH, Cr | | Last pediatric dose visit | Confirm adult provider, issue medication passport | | 1 month after last dose | Serum calcium, phosphate | | 3 months after last dose | CTX, P1NP, serum calcium | | 6 months after last dose (next dose or bisphosphonate bridge) | Full bone panel, DXA if 12 months since last scan | | 12 months after transition | DXA, full bone panel, fracture assessment |

What the Adult Provider Should Do at the First Visit

The first adult appointment with this patient has a specific clinical agenda that differs from a routine osteoporosis consult.

Confirming Continuity of Effect

Check the date of the last denosumab dose first. If more than 6 months have elapsed, request CTX and serum calcium before any further clinical decisions. A CTX rising above the upper limit of normal signals active rebound and requires urgent bisphosphonate initiation, not a wait for the next scheduled appointment.

Reassessing the Indication

Adult providers should ask whether the original indication for denosumab still applies. A child started on denosumab at age 9 for glucocorticoid-induced osteoporosis secondary to nephrotic syndrome may be in remission at age 13. If the steroid exposure has resolved, the risk-benefit ratio for continuing denosumab shifts, and a bisphosphonate transition plan becomes appropriate sooner rather than later.

Fracture Risk Recalculation

FRAX is not validated for patients under 40. The adult provider should use clinical judgment informed by the full fracture history, bone turnover trends, DXA trajectory, and ongoing risk factors. ISCD and the Endocrine Society both recommend against applying adult fracture risk calculators to this age group (6).